Race Oncology 2025 Chairs Address and AGM Presentation
Released
Released
Announcement PDF
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
ASX Announcement
Race Oncology 2025 Chair’s Address and AGM Presentation
24 November 2025 – Race Oncology Limited (“Race”) is pleased to attach a copy of the Chair’s address
and Annual General Meeting (AGM) presentation to shareholders.
Dr Pete Smith, Executive Chair will provide the Chair’s address and conduct the official business of the
meeting. CEO & MD, Dr Daniel Tillett will present a review of recent updates to the shareholders.
Shareholders will be invited toparticipatein a Q+A session with theRace Board and members of the Race
management team after the presentation.
Investors wishing to attend the Annual General Meeting can find access details in the Notice of Meeting
as lodged with the ASX on 22 October 2025 and available via the Company’s website at
www.raceoncology.com/investors. A video recording of the AGM presentation will be released once
available.
The Race team looks forward to welcoming all those shareholders able to attend the meeting.
-ENDS-
About Race Oncology (ASX: RAC)
Race Oncology (ASX: RAC) is an ASX-listed Phase 3 clinical biopharmaceutical company with a dedicated
mission to be at the heart of cancer care.
Race’s leadasset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via
G4-DNA & RNA binding, leading topotent inhibition of theimportant cancer growthregulator MYC.RCDS1
has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent
discoveries have enabled composition of matter IP filings that may provide for 20 years of patent
protection over RCDS1.
Raceis advancing a proprietaryformulation of RCDS1 (RC220) toaddress thehigh unmet needs of patients
across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a
Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm
NSCLC), and a Phase 1a/b programin combination with the anthracyclinedoxorubicin where theaim is to
deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Race Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine,
University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence
agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with
cancer across the world.
Learn more at www.raceoncology.com.
If you have any questions on this announcement or any past RaceOncology announcements, please go to
the Interactive Announcements page at https://announcements.raceoncology.com
Release authorised by:
Board of Race Oncology
info@raceoncology.com
Media contact:
Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
Chair’s Address – Race Oncology 2025 AGM
24 November 2025
Chair’s Address – Race Oncology 2025 AGM
It has been a defining year for Race Oncology - one marked by disciplined execution, scientific insights,
and a strengthening of our clinical and leadership foundations.
The central highlight has been the clinical advancement of our lead oncology asset, RC220. Earlier this
year, we initiated our Phase 1a/b trial of RC220 in combination with doxorubicin for patients with
advanced solid tumours. The first patients have been successfully and safely dosed, validating that RC220
overcomes the historical barrier that prevented (E,E)-bisantrene from being delivered intravenously. This
is a milestone many years in themaking. We have since expanded this programinto Asia, withhigh quality
clinical sites in Hong Kong now open and our South Korean sites to open for recruitment shortly.
At the same time, we have strengthened our clinical capability. The appointments of Professor DanielVon
Hoff to our Clinical Advisory Board, and Dr Jose Iglesias and Dr Simon Fisher into key medical leadership
roles, have already had a tangible impact on our operational readiness and the pace at which we can
advance our programs.
Over the past several months, Race has taken a major step forward in defining the future of RC220.
We filed threepatent applications covering the single active(E,E) isomer of bisantrene, filing Composition
of Matter claims for our programs. Composition of Matter patentsare the most robust form of protection
available for a pharmaceutical asset, as they protect the drug’s chemical structure. This protection if
granted, extends potential exclusivity to around 2045, significantly strengthens our intellectual property
portfolio and enhances the long-term commercial value of RC220 as it advances through clinical
development.
Guided by the discovery that RC220 is a potent binder DNA/RNA G-quadruplex that cansilence themaster
regulator of cell division, the gene and protein MYC, we now have the opportunity to address a critical
unmet need in cancer - specifically, the problem of acquired resistance to targetedoncology drugs such
as the tyrosine kinase inhibitors. This resistance remains one of the most significant challenges in modern
oncology, and the prospect of delaying or preventing it is both clinically and commercially significant.
Planning for our lung cancer trialwhich is seeking to prevent or delay the emergenceof resistance to one
family of targeted drugs, the EGFR tyrosine kinase inhibitors, is well advanced, with protocol and
documents finalised, investigators engaged, and multiple leading Australiansites prepared to commence,
pending final site approvals.
Based on the extensive literatureon MYC, we believe that RC220 may be able to delay the emergence of
resistance to numerous other classes of targeted drugs, key treatments for numerous cancer types and
representing a large a growing market.
In parallel, we have charted a rapid and cost-effective clinical pathway toward potential regulatory
approval of RC220 in relapsed or refractory AML. This includes a bridging Phase 3 programthat connects
the strong historical clinical data from RC110 with our modern RC220 formulation, while aligning with
current FDA expectations such as Project Optimus. This pathway offers the potential for earlier value
realisation in an area of clear unmet need.
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
Importantly, our work in cardioprotection and anticancer activity with doxorubicin continues unchanged
and remains a core priority. Together, these programs position RC220 as a versatile, high-value asset
across solid tumours, orphan oncology indications, and large global markets. Importantly the G4
mechanism moves RC220 from being a chemotherapy drug from the 80’s into the mainstreamof modern
oncology.
Financially, Race remains well funded, with resources in place to progress all existing trialsthrough to the
end of 2027. We have structured our plans prudently: while we continue to advance preparatorywork on
the new NSCLC and AML programs, significant expenditure will only begin when funding thresholds are
met. The Board is actively evaluating all capital and partnership options to ensure we maximise
shareholder value as these opportunities mature.
As we continue to professionalise the Company and in line with our growth and sharpening mission, we
are proposing that Race adopt a new name Racura Oncology. This reflects both the heritageof Race and
the “cura” principle of care, signalling our commitment to delivering meaningful treatments to patients
worldwide. Importantly, thechangein namesignals that Racura today is substantially different tothe Race
of only a couple of years ago.
I would like to acknowledge our team for their extraordinary work in moving from concept of the EGFR
opportunity to full clinical program in under nine months - an exceptional achievement in drug
development without any compromise in quality. The discoveries and opportunities uncovered for RC220
have been inspiring, and the whole team is highly energised by the developments and achievements. I
also want to sincerely thank my fellow directors for their guidance, commitment, and steady leadership
throughout the year.
Finally, to our shareholders: thank you for your ongoing support, engagement, and belief in our work at
Race. We look forward to a highly impactful year ahead.
Thank you.
AT THE
HEART OF
CANCER CARE
Dr Daniel Tillett – CEO & MD
2025 CEO AGM Presentation
N o v e m b e r 2 0 2 5
1
0
A S X : R A C | R A C E O N C O L O G Y L I M I T E D | A B N 6 1 1 4 9 3 1 8 7 4 9
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Summary of recent positive events and evolved strategy of the company
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
1970s – 1990s
Development by
Lederle
Laboratories
>50 studies &
>1,500 patients in
solid and liquid
cancers
Approved in France
for AML, but not
launched due to
formulation
2020 – 2024
Phase 2 AML
studies with
promising data
Reformulated to
solve delivery
issues (RC220)
GMP manufacture
& non-clinical data
Discovery of
cardioprotection
2025
Filed Composition
of Matter patent
over (E,E)-isoform
Mechanism of
action identified to
be via G4-DNA &
RNA binding
MoA silences key
cancer genes
including MYC
Building on our history and progress
New: Phase 3 AML trial bridging RC110 to RC220
Current: Phase 1a/b cardioprotection + anticancer trial of
RC220 in combination with doxorubicin
New: Phase 1a/b trial of RC220 in EGFR* mutated non-
small cell lung cancer aimed at delaying resistance to
market-leading TKI drugs
New: Preclinical & clinical exploration of the
potential of MYC silencing to target the
“undruggable” MYC protein
* Epidermal growth factor receptor
Continued evolution of Race Oncology
2
3
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Indication
Total Addressable
Patients1 Phase 1 Phase 2 Phase 3 Comment
AML (RAC-030)
Acute Myeloid Leukaemia2 US/EU: 50,000
40% response rate in 2
Phase 2 trials3
Bisantrene approved in
France for AML in 1988
Harness-1 (RAC-020)
EGFR Non-small lung cancer
(NSCLC) in combination with
osimertinib (TKI)2
China 445,000
US/EU 95,000
Osimertinib sales exceeds
US$6.6 billion (2024)2
CPACS (RAC-010)
Cardioprotection + anticancer in
combination with doxorubicin in
solid tumours4
Global: 4 million
Patients have been safely
dosed with RC220 and
RC220+Dox4
Phase 1a/b
1. Estimated number of patient per year for each indication. US – USA & Canada; EU - Europe
2. Race Oncology ASX Announcement – Race Announces New Clinical Programs in Acute Myeloid Leukemia and Non-Small Cell Lung Cancer (17 Nov 2025)
3. Race Oncology ASX Announcement – Phase 2 Trial of Bisantrene for AML Meets Predetermined Efficacy Criteria (30 Jul 2024)
4. Race Oncology ASX Announcement – Cardioprotection & Anticancer Data Presented at the European Society for Medical Oncology Congress 2025 (20 Oct 2025)
Phase 3
Phase 1a/b
RC220 clinical pipeline
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Target Indications Key drugs – Brand (generic), marketer, 2024 sales1
Bruton’s Tyrosine Kinase
(BTK)
B-cell malignancies (leukemias and
lymphomas)
• Imbruvica® (ibrutinib), Janssen/Abbvie, US$6.35bn
• Calquence® (acalabrutinib), AstraZeneca, US$3.1bn
• Brukinsa®, (zanubrutinib), BeOne (Beigene), US$2.6bn
• Jaypirca®, (pirtobrutinib), Lilly, US$0.3bn
Epidermal Growth Factor
Receptor (EGFR)
Non-small cell lung cancer (NSCLC)
• Tagrisso®, (osimertinib), AstraZeneca, US$6.6bn
• Amelie® (aumolertinib), Hansoh, US$630m
• Lascluse® (Lazertinib), Janssen, US$450m
Kirsten Rat Sarcoma Virus
(KRAS)
Pancreatic, colorectal, NSCLC
• Lumakras® (sotorasib), Amgen, US$350m
• Krazati® (adagrasib), Mirati/BMS, US$126m
MEK/BRAF Melanoma, colorectal, NSCLC
• Tafinlar® (abrafenib) + Mekinist® (trametinib), Novartis, US$2.1bn
• Braftovi® (encorafenib) + Mektovi® (binimetinib), Pfizer, US$607m
1. Source: company announcements, SEC filings
Treatments where MYC dysregulation is
associated with resistance1
4
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
1. Source: Global Tyrosine Kinase Inhibitors Market By Type (June 2024) - https://marketresearch.biz/report/tyrosine-kinase-inhibitors-market/
Tyrosine kinase inhibitor (TKI) market1
TKIs are the backbone of modern, targeted cancer therapy
5
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Clinical Trials
EGFRm NSCLC, AML & CPACS
6
6
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Incidence
NSCLC2
China 890,000
US/EU 560,000
EGFR
mutations2
China 445,000
US/EU 95,000
Market dynamics
• Third generation EGFR TKIs dominate
the market, led convincingly by
Tagrisso®, which faces patent expiry in
20322
• AstraZeneca’s major rival is Janssen
with Lascluse® in combination with
Rybrevant® (cMET/EGFR antibody)2
• Numerous third generation TKIs in
development, especially in China1
• When patients progress on TKIs they
have few options and limited life
expectancy2
Opportunity
Delaying the emergence of resistance would be of great
value to patients and marketers of EGFR inhibitors –
RC220 could be a significant addition to existing
standards of care
Target:
Epidermal
Growth Factor
Receptor
(EGFR)
Major Players – 3rd Generation TKIs
Brand Generic Manufacturer
2024
sales
(US$m)1
Tagrisso® Osimertinib AstraZeneca 6,580
Amelie® Aumolertinib Hansoh 630
Ivesa® Furmonertinib Shanghai Allist 500
Lascluse® Lazertinib Janssen 450
EGFR-mutated non-small cell lung cancer
There is a large existing market for TKIs targeting the epidermal growth factor receptor (EGFR)
7
1. https://announcements.raceoncology.com/announcements/7181421
2. Frost & Sulivan, Innovative Small Molecule Drug Market Report. (2024).
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
A Race Oncology sponsored Phase 1a/b trial of RC220 + osimertinib in
EGFRm NSCLC patients who are tumour positive by ctDNA1 with the aim of
delaying TKI resistance
• Endpoints (results): Safety, maximum tolerated combined dose, changes in ctDNA1
positivity, progression free survival and overall survival
• Sites: Five in Australia (Sydney, Melbourne, Brisbane)
• Cost: ~A$11.5m before R&D tax rebate
• Time: Phase 1a (9 – 12 months), Phase 1b (~9 months)
• First patient: Q1 2026 (contingent upon approvals)
• Data: Trial is open label, with frequent data read-outs and news flow throughout
2026 & 2027 on progress and results. First efficacy results will be reported in 2026
Potential for US FDA
Accelerated Approval
HARNESS-1 highly advanced with
HREC (ethics) application
submitted, CROs selected, and
sites and clinicians recruited
1. ctDNA = circulating tumour DNA
HARNESS-1. HAlt Resistance in NSCLC with
EGFR Sensitising mutationS
Addressing an urgent unmet need for patients who progress on third generation TKIs
8
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Screen EGFRm NSCLC patients on osimertinib (Osi) maintenance for tumour presence by
ctDNA (~100 patients)
ctDNA
Screening
Interventional
Phase 1a – dose escalation
RC220 dose escalation + standard
Osi to identify the maximum
tolerated combined dose (MTCD)
Lower Dose
RC220 + Osi
Higher Dose
RC220 + Osi
Optimal RC220 + Osi
Dose Progression
Free Survival (PFS)
Open label dose escalation &
safety study (12-40 patients)
Phase 1b – dose expansion
Blinded & randomised two dose levels to identify
optimal RC220 + standard Osi dose (~40 patients)
HARNESS-1. Phase 1a/b Trial Overview
Proof of concept trial demonstrating that RC220 can delay resistance to TKIs
9
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
HARNESS-1 Trial Checklist
Requirement Feature of EGFRm NSCLC Check
Large existing market >US$10 billion p.a. for EGFRm TKIs
Supportive preclinical &
clinical data
G4 binding targets more than three of the known EGFRm TKI
resistance pathways
High clinical need Very high – few options for EGFRm TKI progressing patient
Proprietary companion
drug
3rd generation EGFR TKIs
Many pharma players 14 EGFRm TKI approved in China & USA, 8 in Phase 3
Rapid & low-cost POC trial ctDNA(+) to ctDNA(-)
Large effect size Use of ctDNA
Possibility of FDA
accelerated approval
Datopotamab from Phase 2 data (2025)
Zongertinib from Phase 1b data – 80 patients (2025)
Sevabertinib from Phase 1/2 data - 70 patients (2025)
Template trial design ctDNA approach can be applied to resistance of any TKI
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Adult r/r AML1
≥2nd Line
n = 40
Randomise 1.5:1:1.5:1
RC220 DL 2
(250mg/m2 x 7d;
n = 12)
RC110 DL 1
(250mg/m2 x 4d;
n = 8) RC220 Optimum
Dose3
(n = 97)
Part A (20) +
Part B (77)
Establish
Optimum
Dose2
Part A – RC110/RC220 Bridging & Project Optimus Part B – Dose Expansion
1. r/r AML, relapsed and refractory acute myeloid leukemia.
2. Criteria: Efficacy, PK equivalence, safety, tolerability.
3. Dichotomous Endpoint, One-Sample Study: 25% base & 40% ORR; p=0.05; power=0.9
RC220 DL 1
(250mg/m2 x 4d;
n = 12)
RC110 DL 2
(250mg/m2 x 7d;
n = 8)
FDA Approval Path
HiDAC Control
(n = 40)
FDA
Meeting
AML Phase 3 Trial (RAC-030)
A rapid & affordable path to FDA-approval in the original indication of bisantrene
11
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Part 1: Advanced solid tumour patients how have the
potential to benefit from doxorubicin therapy
Part 2: Anthracycline naïve solid tumour patients who have the potential to
benefit from doxorubicin therapy
Patient cohorts (n=3)
receive increasing doses of
RC220
First cycle – RC220 alone
Subsequent cycles - RC220
with 60mg/m2 doxorubicin
Objective Part 1:
Establish maximum tolerated combination dose (MTCD)
n=15-33 patients
All patients receive RC220 + doxorubicin combination from first cycle at
RC220 dose determined to be safe in Part 1
Endpoints
Safety and measures of efficacy, plus:
standard & advanced cardiac markers including VO2peak, m6A levels
& anticancer efficacy
Objective Part 2:
Strengthen data on safety of combination, early efficacy data
Establish degree of cardioprotection of combination
n=20 patients
RC220 Phase 1 cardioprotection + anticancer
synergy trial – CPACS-1 (RAC-010)
Demonstrate RC220’s ability to protect the heart and increased anti-cancer efficacy
12
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Intellectual Property
13
13
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
• Race has discovered that bisantrene can exist in three forms that change when exposed
to light – the (E,E), (E,Z) and (Z,Z) isoforms
• Photoisomerisation of bisantrene was not known prior to Race’s discovery
• Only (E,E)-bisantrene has anticancer activity
• Three new patent applications filed Sept 2025
• Cover composition of matter, manufacturing at scale, RC220 formulation, and
protection from light in clinical use – “patent thicket”
• Composition of mater claims meet all the requirements for patent allowance - non-
obviousness, novelty and utility
• Advice from IP legal council is supportive of the patentability of these claims
Composition of matter claims are the strongest form of IP protection in the
pharmaceutical industry, which if granted, will add significantly to value any future
licensing or partnering transactions
Robust IP - Recent patent filings
Foundation for 20 years of the strongest composition of matter IP protection
14
Milestones & Highlights
15
2026
• Filing of US IND for Phase 3 AML (RAC-030) trial
• Update on progress of CPACS (RAC-010) trial dose escalation
• Investor day – deep dive on recent events
• First patient treated in Phase 3 AML trial
• Patient data on MYC-targeting by RC220
• First patient treated in HARNESS-1 (RAC-020) trial
• Initiation of Phase 3 readiness CMC* program
• Data on RC220 combination with other drug classes
• Early RC220 efficacy data from HARNESS-1 trial
• Completion of accelerated patent examination of composition
of matter claims for (E,E)-bisantrene
2027
• First patient treated in Phase 1B CPACS (RAC-010) trial
• Completion of Phase 3 AML trial RC110/RC220 bridging stage
• First human efficacy data on the cardioprotective effects of RC220
• Publication of (E,E)-bisantrene mechanism of action
• Completion of Phase 1A HARNESS-1 (RAC-020) Trial providing
proof-of concept clinical data
• First patient treatment in Phase 1B HARNESS-1 (RAC-020) trial –
FDA Project Optimus data
• Initiation of pivotal HARNESS-2 Phase 2b trials in China & USA/Rest
of World
• Initiation of pivotal CPACS-2 Phase 2b trial
• Initiation of Phase 3 AML efficacy expansion stage
1. All dates are estimates and subject to change
Future drivers of shareholder value1
Significant news flow and clinical data from three open-label trials in 2026 & 2027
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
16
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
17
In Phase 3 with a derisked & clinically proven
anticancer drug
Solving real & significant health problems –
permanent damage caused by chemotherapy
& TKI resistance
Targeting major existing markets as a companion
to anthracyclines (US$1.5bn) and EGFR TKI
(>US$10bn)
(E,E)-bisantrene silences MYC expression. MYC
dysregulated in >70% of cancers, but considered
‘undruggedable’ – wide opportunity
Composition of matter claims filed, opening-up
20 years of IP exclusivity for RC220 if granted
Key highlights of Race Oncology
1
5
2
3
4
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
1. There has been no change to the 2021 clinical programs
…but some highly valuable additions. CPACS and AML remain clear priorities for us
2. The timeline to a commercial outcome has not increased
Update has significantly DECREASED the timeline – we now have many more opportunities to
commercialise
3. HARNESS-1 requires $11.5m to start - $5m already raised
HARNESS-1 lung cancer trial can start in 2025 with first patients in Q1 2026
4. The new trials will be run
All announced trials can be funded from conversion of the $1.25 options. This is the best choice
for shareholders, not the ONLY funding choice – early option conversion is the most shareholder
friendly way of funding the new programs
Final takeaway
18
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
19
Questions
R a c e O n c o l o g y
A T T H E H E A R T O F C A N C E R C A R E
A
T
T
H
E
H
E
A
R
T
O
F
C
A
N
C
E
R
C
A
R
E
Contact DANIEL TILLETT JANE LOWE
CEO Investor & Media Relations
+61 411 117 774
+61 2 8051 3043
jane.lowe@irdepartment.com.au
daniel.tillett@raceoncology.com
Authorised for release by the Board
www.raceoncology.com
Share your feedback
Discover